linjc16/ctgov huggingface dataset:
1 Versus 2 Hours Post Meal Glucose Monitoring in Gestational Diabetes on Treatment

Study Overview
=================
Brief Summary
-----------------
A study to compare between 1 and 2 hours post meal blood glucose monitoring in patients with Gestational Diabetes Mellitus requiring treatment.

Detailed Description
-----------------
This study involves all pregnant women who attended our antenatal clinic with Gestational Diabetes Mellitus requiring treatment. They will be randomised to either 1 or 2 hours post meal self blood glucose monitoring. The blood sugar profile is a staggered 7 points. They are followed up in the research clinic until delivery.

Official Title
-----------------
1 Versus 2 Hours Post Meal Self Monitoring Blood Glucose in Gestational Diabetes Mellitus on Treatment-A Prospective Randomised Controlled Trial

Conditions
-----------------
Gestational Diabetes, Treatment Adherence

Intervention / Treatment
-----------------
* Other: Home blood glucose monitoring


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Gestational diabetes diagnosed based on National Institute for Health and Care Excellence guideline requiring treatment either with metformin alone or combined with insulin Exclusion Criteria: type 1 and 2 diabetes bad obstetrics history underlying medical disorders such as Systemic Lupus Erythematosus fetal anomaly delivery elsewhere

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1 hour<br>Blood glucose monitoring comprises of 1 hour post meal | Other: Home blood glucose monitoring<br>* Self monitoring of capillary blood glucose<br>|
| 2 hours<br>Blood glucose monitoring comprises of 2 hours post meal | Other: Home blood glucose monitoring<br>* Self monitoring of capillary blood glucose<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mode of delivery | route | from point of randomization to birth of the neonate | 
| Gestational age | in weeks | from point of randomization to birth of the neonate | 
| Fetal weight | in gram | from point of randomization to birth of the neonate | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Maternal complications | postpartum haemorrhage, perineal tear | from point of randomization to birth of the neonate | 
| perinatal complications | intrauterine death, macrosomia, admission to neonatal intensive care unit | from point of randomization to birth of the neonate | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Gestational diabetes, treatment, glucose monitoring
Clinical Evaluation of Navigated 3D Ultrasound Multicentre Study

Study Overview
=================
Brief Summary
-----------------
3D ultrasound is a new modality used in image guided neurosurgery. a multicentre study is started for the evaluation of this tool as a means for achieving total resection of brain tumors at greater safety.

Detailed Description
-----------------
The degree of resection as judged by the surgeon is recorded at the end of surgery for each patient, and then compared with the postoperative MRI. Neurological status before and after surgery, QOL before surgery and at follow-up as well as survival is recorded.

Official Title
-----------------
Clinical Evaluation of Navigated 3D Ultrasound Multicentre Study

Conditions
-----------------
Brain Neoplasms

Intervention / Treatment
-----------------
* Device: use of navigated 3D ultrasound during surgery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Supratentorial glioma Exclusion Criteria: Not willing to participate in study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: use of navigated 3D ultrasound during surgery|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Neuronavigation, Ultrasound, Brain tumour surgery, Biopsy, Histopathology, Intraoperative imaging, 3D ultrasound imaging
Long-Term Study of Multi-target Therapy as Maintenance Treatment for Lupus Nephritis

Study Overview
=================
Brief Summary
-----------------
An multi-site, randomized, prospective study to compare the efficacy and safety of multi-target therapy as continuous induction and maintenance treatment versus CTX- Aza therapy.

Detailed Description
-----------------
Azathioprine (AZA) has been used for maintenance therapy of lupus nephritis for many years. We compare the efficacy and safety of multi-target therapy as continuous induction and maintenance treatment vs CTX-Aza.

Official Title
-----------------
Research Institute of Nephrology, Jinling Hospital,

Conditions
-----------------
Lupus Nephritis

Intervention / Treatment
-----------------
* Drug: Multi-target therapy
* Drug: Azathioprine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who signed written informed consent form SLE patient, aged between 18-65 years, female or male; Patients diagnosed lupus nephritis according to ISN/RPS 2003 classification criteria, class Ⅲ, Ⅳ,Ⅳ+Ⅴ, Ⅲ+Ⅴ or Ⅴ LN by renal biopsy All patients had received induction therapy for 6 months with multi-therapy (FK506 + MMF) or intravenous CTX pulses. Patients were recruited when received partial remission or complete remission after 6 months induction therapy. Complete remission: proteinuria <0.4 g/24h, negative urine sediment, serum albumin >35 g/L, elevated scr <0.3mg/dl, no extra-renal complications; Partial remission: proteinuria <1.0 g/24h, urine RBC <50X104/ml without casts, serum albumin > 30 g/L, elevated Scr <0.3mg/dl,no extra-renal complications. Exclusion Criteria: Patients who didn't sign written informed consent form or could not obey the protocol. Patients who didn't received the CR or PR criterion. Patients who have impaired liver function, with ALT/GPT or AST/GOT twice more than the normal upper limit or who have active hepatitis. WBC <3000/mm3 in peripheral blood . Patients with central nervous system symptoms. -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Multi-target therapy<br>(Tarcrolimus+mycophenolate mofetil) | Drug: Multi-target therapy<br>* Tacrolimus (1-3mg/d) and mycophenolate mofetil(0.5-0.75g/d)<br>* Other names: Tacrolimus+mycophenolate mofetil;|
| Active Comparator: Azathioprine<br>Aza | Drug: Azathioprine<br>* 1.0-2.0mg/kg/d<br>* Other names: Aza;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To compare the efficacy and safety of multi-target therapy as maintenance treatment for lupus nephritis with Aza. |  | 18 months |
Freeze-all Policy in Poor Responders

Study Overview
=================
Brief Summary
-----------------
To compare the effects of fresh embryo transfers (ET) and elective frozen-thawed embryo transfer cycles in poor ovarian responders.

Official Title
-----------------
Fresh Versus Frozen Embryos for Infertility in the Poor Responders as Defined by the Bologna Criteria

Conditions
-----------------
Infertility, Female

Intervention / Treatment
-----------------
* Other: Freeze-all policy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients that fulfill the Bologna criteria [at least 2 of the following 3 features must be present: (i) advanced maternal age or any other risk factor for POR; (ii) a previous POR; and (iii) an abnormal ovarian reserve test (ORT)] if the progesterone serum level was ≤1.5 ng/mL on the trigger day. body mass index 18-32 kg/m2 Both partners are able to provide written informed consent. At least 1 good quality embryo on day 3 after egg collection on day 3 according to the Istanbul consensus (7-8 cells; with symmetric blastomeres and <10% fragmentation by volume). Endometrial thickness ≥8 mm on trigger day. a normal uterine cavity on ultrasound. IVF/ICSI with only fresh semen Exclusion Criteria: Pre-implantation genetic testing is being planned. if they had severe endometriosis, uterine pathology (myomas, adenomyosis, endocrinopathies, adhesions, acquired or congenital abnormalities), untreated tubal hydrosalpinges, ovarian tumor, recurrent spontaneous abortion, implantation failure after ≥ 2 fresh or frozen ET.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Freeze-all<br>Good quality embryos (either day 3 or 5) will be frozen and subsequent frozen embryo transfer will be arranged within three months of the egg retrival. | Other: Freeze-all policy<br>* A policy of freezing all the embryos followed by subsequent thawed frozen embryo transfer<br>|
| No Intervention: Fresh embryo transfer<br>Women will undergo fresh embryo transfer at the cleavage (day 3) or blastocyst stage (day 5). | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Livebirth rate | The proportion of women in the population who had at least one live baby. | 32 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pregnancy rate | Positive pregnancy test at two weeks +/- three days after embryo transfer | 2 weeks | 
| Clinical pregnancy rate | The presence of at least one fetal heartbeat at ultrasound between six and eight weeks of gestation | 6-8 weeks |
New Devices to Measure the Intracuff Pressure

Study Overview
=================
Brief Summary
-----------------
Over the past 5 years, there has been a change in clinical practice with the use of cuffed instead of uncuffed endotracheal tubes in infants and children. Two manufacturing companies have recently introduced syringe-like devices to the market which allow the measurement of the intracuff pressure. This study proposes to prospectively compare the intracuff pressure from these devices with the gold standard technique (manometer).

Conditions
-----------------
Patients Intubated With a Cuffed Endotracheal Tube

Intervention / Treatment
-----------------
* Device: Syringe device


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years of age or younger, undergoing a procedure requiring endotracheal intubation with a cuffed ETT. Exclusion Criteria: None

Ages Eligible for Study
-----------------
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Syringe device<br>Endotracheal tube cuff pressure measured by 2 new syringe devices. | Device: Syringe device<br> <br> * Other names: AG Cuffill;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cuff pressure |  | One time in the OR prior to the start of surgery |
Long Term Extension Study is Designed to Monitor Long-Term Efficacy and Safety of Miravirsen Sodium in Combination With Telaprevir and Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1 Infection

Study Overview
=================
Brief Summary
-----------------
Long Term Observational Extension Study Designed to Monitor Long-Term Efficacy and Safety of Miravirsen Sodium in Combination with Telaprevir and Ribavirin in Subjects with Chronic Hepatitis C Virus Genotype 1 Infection

Official Title
-----------------
Long-term Extension to a Phase 2, Open-Label, Clinical Trial of Miravirsen Sodium in Combination With Telaprevir and Ribavirin in Null Responders to Pegylated-Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C Virus Genotype 1 Infection

Conditions
-----------------
HCV

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Participated in Study SPC3649-205 (this would include those who completed study SPC3649-205, those who discontinued or terminated the study early for whatever reason (including treatment failure) and those who opted to receive approved therapy for the treatment of HCV infection). Exclusion Criteria: Those unwilling to provide informed consent for participation in this study. Subjects who have received investigational drug therapy after discontinuation, termination, or successful completion of Study SPC3649-205.

Ages Eligible for Study
-----------------
Minimum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Cohort<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Participants with adverse changes in liver ultrasound results |  | Up to 48 months |
Colorectal Cancer Screening Using Stool DNA-based SDC2 Methylation Test

Study Overview
=================
Brief Summary
-----------------
A study of colorectal cancer screening using stool DNA-based SDC2 methylation test

Official Title
-----------------
Colorectal Cancer Screening Using Stool DNA-based SDC2 Methylation Test

Conditions
-----------------
Colorectal Cancer, Colon Polyp, Healthy

Intervention / Treatment
-----------------
* Diagnostic Test: Earlytect Colon Cancer


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient who agreed the clinical trial and signed informed consent High risk patient for colorectal cancer (family history of colorectal cancer, history of adenomatous polyp excision, inflammatory bowel disease > 15 years, or history of hereditary colorectal cancer) Patient who scheduled to receive colonoscopy Stool > 20g before bowel preparation for colonoscopy Exclusion Criteria: No high risk patient under 60 years History of colorectal cancer Stool < 20g or sample after bowel preparation Diarrhea or liquid stool which cannot be evaluated Patient who is judged as not suitable for clinical trial including a psychiatric disorder by a physician

Ages Eligible for Study
-----------------
Minimum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Screening
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Colorectal cancer<br>Confirmed colorectal cancer under colonoscopy | Diagnostic Test: Earlytect Colon Cancer<br>* A diagnostic device measuring syndecan 2 methylation status in stool DNA to detect colorectal cancer<br>|
| Experimental: Colon polyp<br>Confirmed colorectal polyp under colonoscopy | Diagnostic Test: Earlytect Colon Cancer<br>* A diagnostic device measuring syndecan 2 methylation status in stool DNA to detect colorectal cancer<br>|
| Active Comparator: Healthy<br>Confirmed no cancer nor polyp under colonoscopy | Diagnostic Test: Earlytect Colon Cancer<br>* A diagnostic device measuring syndecan 2 methylation status in stool DNA to detect colorectal cancer<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| SDC2 methylation in stool DNA | positive ratio of SDC2 methylation | 1 year | 
| sensitivity and specificity of EarlyTect |  | 1 year |
Efficacy and Safety of Aspirin and Clopidogrel in the Atrial Fibrillation With Low or Moderate Stroke Risk

Study Overview
=================
Brief Summary
-----------------
This study was designed in order to evaluate and compare the efficacy and safety between aspirin and clopidogrel in the patient with low stroke risk Atrial Fibrillation (AF).

Detailed Description
-----------------
Efficacy outcome will be evaluated the major cerebro-cardiovascular event including stroke, cardiovascular death, and myocardial infarction during 1 year-medication period. In addition, safety outcome will be evaluated the gastrointestinal responses including peptic ulcer and upper gastrointestinal bleeding events to both study drugs by repeated gastroenteroscopic examinations before and after medication by GI specialist.

Official Title
-----------------
Comparison of Efficacy and Safety Between Aspirin and Clopidogrel in the Atrial Fibrillation With Low or Moderate Stroke Risk

Conditions
-----------------
Atrial Fibrillation

Intervention / Treatment
-----------------
* Drug: Aspirin
* Drug: Clopidogrel


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Man or Women > 20 years old newly detected AF (CHA2DS2VASc index score: 1) Patient who needs antiplatelet therapy using aspirin clopidogrel for stroke prevention volunteer only childbearing aged women who takes proper oral contraceptive Exclusion Criteria: No specific contraindication or any history of hypersensitivity of Clopidogrel or aspirin Patient with active GI bleeding or bleeding tendency or major bleeding history less than 1 year of residual expected life Pregnant or breast-feeding women Other causes, determined by charged physician Patient with definite GERD who needs special treatment Patient who needs to take NSAID (Non-Steroidal Anti-Inflammatory Drug) for more than 2 weeks

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Intervention: Clopidogrel<br>Case management with clopidogrel 75mg once daily is provided for stroke prevention in AF patient. | Drug: Clopidogrel<br> <br> |
| Experimental: Control: Aspirin<br>Usual care with aspirin 100mg once daily is provided for stroke prevention in AF patient. | Drug: Aspirin<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Major Cerebrovascular and cardiac events including stroke, CV death, MI | Number of each event | 1 year after randomization | 
| Major gastrointestinal event including peptic ulcer disease and bleeding | Number of each event | 1 year after randomization |
Prevalence of Cervical Extension of the Thymus in Children

Study Overview
=================
Brief Summary
-----------------
This prospective, observational study included all pediatric patients who were referred to the radiology department for neck ultrasonography between August-October 2018. A high-frequency probe was implemented and 220 patients were examined.

Detailed Description
-----------------
This prospective single-centered study was approved by the Institutional Review Board for Ethical Issues in Clinical Research and is compatible with the Declaration of Helsinki. The patients referred to the radiology department for the neck US with various clinical indications between August-October 2018 were included in the study. The informed consent was taken from the parents of the patients. The patients who had any systemic illness, were treated for malignancy or had any history of lower neck or chest surgery, were excluded. The neck US was performed by two radiologists. The length of the extended thymus, from the upper margin of the manubrium to the superior edge of the thymic tissue on the transverse plane, was measured in millimeters and recorded. al analysis of the data was performed in SPSS, Version 24 program (IBM, Armonk, New York). Pearson Chi-Square Test was used in comparing categorical data between groups.

Official Title
-----------------
Prevalence of Cervical Extension of the Thymus in Children- A Prospective Study

Conditions
-----------------
Prevalence of Cervical Extension of the Thymus

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The patients referred to the radiology department for the neck US with various clinical indications between August-October 2018 were included in the study. Exclusion Criteria: The patients who had any systemic illness, were treated for malignancy, or had any history of lower neck or chest surgery, were excluded.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 0 | As our trial has no intervention, so there were no positive or negative primary effects | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Thymus; Cervical extension; Pediatrics;